OLYSIO

New Zealand - English - Medsafe (Medicines Safety Authority)

Active ingredient:
Simeprevir sodium 154.4 mg equivalent to simeprevir 150.0 mg
Available from:
Janssen-Cilag (New Zealand) Ltd
INN (International Name):
Simeprevir sodium 154.4 mg (equivalent to simeprevir 150.0 mg)
Dosage:
150 mg
Pharmaceutical form:
Capsule
Composition:
Active: Simeprevir sodium 154.4 mg equivalent to simeprevir 150.0 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Gelatin Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Sodium laurilsulfate
Prescription type:
Prescription
Manufactured by:
Janssen Pharmaceutica NV
Therapeutic indications:
Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection.
Product summary:
Package - Contents - Shelf Life: Blister pack, PVC-PE-PVDC blister & Al push-through foil - 7 capsules - 24 months from date of manufacture stored at or below 30°C protect from light - Blister pack, PVC-PE-PVDC blister & Al push-through foil - 28 capsules - 24 months from date of manufacture stored at or below 30°C protect from light
Authorization number:
TT50-9385
Authorization date:
2013-09-02

Similar products

Search alerts related to this product

Share this information